FDA working to phase out Use of certain Antibiotics to make Food-producing Animals gain Weight

Will the FDA’s 2013 Antibiotic Guidance clean up Farming?

A long waited step to preserve the effectiveness of antibiotics drugs critical to human health.

The Food and Drug Administration (FDA) is implementing a voluntary plan with industry to phase out the use of certain antibiotics for enhanced food production.

Some farmers have been exploiting antibiotics by adding to the animal feed or drinking water of cattle, hogs, poultry and other food-producing animals to help them gain weight faster or use less food to gain weight.

Because all uses of antimicrobial drugs, in both humans and animals, contribute to the development of antimicrobial resistance, it is important to use these drugs only when medically necessary. Governments around the world consider antimicrobial-resistant bacteria a major threat to public health. Illnesses caused by drug-resistant strains of bacteria are more likely to be potentially fatal when the medicines used to treat them are rendered less effective.

The FDA’s actions will limit the medications to their original purpose — to treat infections — and require veterinarians to dispense the drugs.

FDA Consumer Update:

Phasing Out Certain Antibiotic Use in Farm Animals
U.S. Food and Drug Administration, Dec. 11, 2013

Media Press Releases:

Related posts:

IVF: Women’s Age a Key Predictor of Failure and affecting each Stage of Treatment

Factors Associated with Failed Treatment: an Analysis of 121,744 Women Embarking on Their First IVF Cycles

Women's age affects every stage of IVF
A woman’s age affects the outcome of every single step of In Vitro Fertilization treatment, according to a University of Aberdeen study. This is the first study of its kind to break down failure rates for each stage of #IVF for different age groups.

A woman’s age affects the outcome of every single step of In Vitro Fertilization treatment, according to a University of Aberdeen study.

This is the first study of its kind to break down failure rates for each stage of IVF for different age groups.


In-vitro fertilization (IVF) is the treatment of choice for unresolved infertility. It comprises a number of key steps, each of which has to be negotiated before the next is attempted, but the factors which are associated with failure at each stage have not been reported.

Methods and Findings:
We analyzed anonymised national data on women undergoing their first fresh autologous IVF and intracytoplasmic sperm injection (ICSI) cycle in the United Kingdom between 2000 and 2007 to predict factors associated with overall lack of livebirth as well as the chance of non-progress at different stages of an IVF cycle. A total of 121,744 women were included in this analysis. Multivariable models underlined the importance of increased female age and duration of infertility, lack of previous pregnancy, and a diagnosis of tubal or male factor infertility in predicting the risk of not having a live birth in an IVF treatment. At each stage, a woman’s chance of proceeding to the next stage of IVF treatment is affected by increased age and duration of infertility. The intention to use intra-cytoplasmic sperm injection (ICSI) is associated with a decreased risk of treatment failure in women starting an IVF cycle (RR 0.93, 99% CI 0.92, 0.94) but this association is reversed at a later stage once fertilisation has been confirmed (RR=1.01, 99%CI 1.00, 1.03).

Female age is a key predictor of failure to have a livebirth following IVF as well as the risk of poor performance at each stage of treatment. While increased duration of infertility is also associated with worse outcomes at every stage, its impact appears to be less influential. Women embarking on ICSI treatment for male factor infertility have a lower chance of treatment failure but this does not appear to be due to increased chances of implantation of ICSI embryos.


New Drug Approach that could lead to Cures for wide Range of Diseases

Restoration of testis function in hypogonadotropic hypogonadal mice harboring a misfolded GnRHR mutant by pharmacoperone drug therapy

OHSU researchers develop new drug approach that could lead to cures for wide range of diseases
The ability of drugs called ‘pharmacoperones’ to rescue misfolded proteins and return them to normalcy could someday be an underlying cure to a number of diseases, scientists say

” A team led by a longtime Oregon Health & Science University researcher has demonstrated in mice what could be a revolutionary new technique to cure a wide range of human diseases — from cystic fibrosis to cataracts to Alzheimer’s disease — that are caused by “misfolded” protein molecules.

Misfolded protein molecules, caused by gene mutation, are capable of maintaining their function but are misrouted within the cell and can’t work normally, thus causing disease. The OHSU team discovered a way to use small molecules that enter cells, fix the misfolded proteins and allow the proteins to move to the correct place and function normally again. “

Continue reading OHSU researchers develop new drug approach that could lead to cures for wide range of diseases,
Oregon Health and Science University, 09 Dec 2013


Cervical Cancer Information Leaflet

If you have any concerns about cervical cancer please speak to your G.P.

We know that earlier diagnosis of cervical cancer can help save lives, so our message to women is to start talking, spread the word about signs and symptoms of the diseases, and help break down the wall of embarrassment that could put their lives at risk.

Cervical Cancer Information Leaflet by @TheEveAppeal on Flickr
If you have any concerns about cervical cancer please speak to your G.P.

Download The Eve Appeal Cervical Cancer Information Leaflet
By The Eve Appeal gynaecology cancer research fund, London UK – on Facebook and Twitter

Watch the Diaporama, and the DES research photo set on flickr®  DES Diethylstilbestrol's photostream on Flickr

If you already have a flickr® account, add us as a contact
Email your photos to des.daughter@gmail.com with a short description and title :-)

Our Posts about – Cervical CancerOvarian CancerWomen’s Health

Autism: Susan Boyle’s Relief at discovering that she has Asperger’s Syndrome

Singer reveals she was diagnosed a year ago and now feels “relieved and a bit more relaxed about myself”

Susan Boyle: my relief at discovering that I have Asperger's
“I think people will treat me better because they will have a much greater understanding of who I am and why I do the things I do” says Susan Boyle

As Scottish singing sensation Susan Boyle’s extraordinary career continues, the singer reveals for the first time that she has Asperger’s syndrome (AS), a high-functioning form of autism.

Thinking she had a more serious illness – Susan had been misdiagnosed after complications at birth and carried the “label” brain damaged throughout her life – she went to seek another diagnosis from a Scottish specialist. Susan now feels relieved and a bit more relaxed about herself.

Big Pharma spending one Million Dollars a Week on Sponsored “Educational Events” in Australia

A Million Dollars A Week, The Global Mail, 2013

A Million Dollars A Week
The Global Mail’s new database exposes the murky relationships between drug-makers and doctors.

Pharmaceutical companies are banned from advertising prescription drugs directly to Australian consumers. But they can promote their products to doctors and other health professionals, including through their sponsored “education events”.

Explore the Data Visualisation, The Global Mail

Read A Million Dollars A Week, The Global Mail
by Debra Jopson, Clare Blumer, Mike Seccombe, 26 April 2013

Read The Great Pill Pu$h, The Global Mail, 21 Nov 2013

Exposition aux Mélanges de Substances Chimiques: La Conférence 2013 de l’ANSES


Conference BfR / DTU / Anses – Exposition aux mélanges de substances chimiques : Quels défis pour la recherche et l’évaluation des risques ?

Conference BfR / DTU / Anses - Exposition aux mélanges de substances chimiques : Quels défis pour la recherche et l’évaluation des risques ?
Du 10/12/2013 au 11/12/2013 – programme

Maison de la RATP – Espace du Centenaire – 189, rue de Bercy – 75012 Paris

Notice de l’ANSES:
En raison d’une très forte affluence, nous avons atteint les capacités d’accueil de l’espace du Centenaire. C’est pourquoi, nous ne sommes plus en mesure d’enregistrer de nouvelles inscriptions. Toutefois, nous mettons à votre disposition une inscription sur liste d’attente qui permettra, en cas de désistement, d’accepter à nouveau des participants. Une réponse positive sera envoyée, le cas échéant, le 4 décembre 2013 au plus tard.

Communiqué de Presse:
L’homme est exposé à de multiples substances chimiques présentes dans son environnement, notamment par l’alimentation, l’eau, l’air, le sol et les biens de consommation. Au cours des dernières décennies, les effets potentiels des cocktails de substances chimiques sur l’homme et son environnement sont devenus pour de nombreux pays dans le monde une préoccupation majeure. C’est pourquoi, les experts scientifiques et les gestionnaires du risque se sont emparés de ce défi en soutenant des programmes de recherche et en développant de nouvelles méthodologies d’évaluation des risques.
Sur cette thématique, plusieurs rapports récents ont mis en exergue les besoins en recherche en Europe(1) et aux USA, dont une recherche du NIEHS sur les cocktails chimiques datant de novembre 2012.
Dans ce contexte, l’Anses, le DTU (Danmarks Tekniske Universitet / Institut national de sécurité alimentaire du Danemark) et le BfR (Bundesinstitut für Risikobewertung / Institut fédéral d’évaluation des risques d’Allemagne) ont décidé d’organiser un colloque présentant l’état de l’art des travaux de recherche sur les mélanges de substances chimiques. Ce colloque rassemblera chercheurs et scientifiques d’agences européennes et d’outre-Atlantique afin de promouvoir les échanges de pratiques et de connaissances au niveau international.

Les discussions abordées au cours de ce colloque auront pour thème :

  • Les connaissances récentes et actuelles sur les effets des mélanges chimiques sur la santé humaine, prenant en compte les diverses classes de substances chimiques, les voies d’exposition et les données expérimentales existantes,
  • Les méthodologies d’évaluation des risques des mélanges chimiques,
  • Les sources d’incertitude et les principales lacunes en termes de connaissances sur lesquelles la recherche future doit faire porter ses efforts,
  • La validité des modèles de prédiction des effets cumulés, les preuves expérimentales et les utilisations pratiques pouvant en être déclinées,

Les opportunités pour le développement de projets collaboratifs interdisciplinaires.

Sources: Anses – Agence nationale de sécurité sanitaire de l’alimentation, de l’environnement et du travail, Mis à jour le 28/11/2013

Voir également: Ces “effets cocktail” qui menacent l’homme
par Yann Verdo, Les Echos, 06/12/2013
Plus sur le BPA – perturbateurs endocriniens – pesticides

Every prescription drug that has been recalled by the FDA…

was first proven to be “safe and effective” by the FDA…

Every Drug that has been recalled by the FDA… was first proven to be safe and effective by the FDA…
The FDA issued a warning but didn’t ban DES!

was first proven to be “safe and effective” by the FDA…

Sources: Secrets of the Fed

All our posts about Prescriptions Drugs – FDA – Health News

On Flickr®

Watch the Diaporama, and the Art photo set on  DES Diethylstilbestrol's photostream on Flickr

If you already have a flickr® account, add us as a contact
Email your photos to des.daughter@gmail.com with a short description and title :-)

MR-guided Ultrasound offers NonInvasive Treatment for Breast Cancer

Sound Waves as Breast Cancer Tx: Wave of Future?

MR-guided Ultrasound Offers Noninvasive Treatment for Breast Cancer
Radiological Society of North America: professional membership society committed to excellence in patient care through education and research

A technique that uses focused ultrasound under magnetic resonance (MR) guidance to heat and destroy tumors may offer a safe and effective treatment  for breast cancer, according to research being presented this Wednesday at the annual meeting of the Radiological Society of North America (RSNA).

To assess safety and feasibility of non-invasive high intensity 3T MR guided focused Ultrasound (MRgFUS) ablation of biopsy-proven invasive ductal breast cancer (IDC) (stage T1 M0 N0) before surgical resection and sentinel lymph node biopsy.

Our retrospective study included 12 patients with unifocal biopsy-proven IDC, scheduled and consented to lumpectomy and sentinel lymph node biopsy. We use 3T MRI exam (Discovery 750, GE; Gd-BOPTA, Bracco) to confirm presence and treatable location of enhancing lesion (less than 2 cm). Patient underwent day-surgery single session MRgFUS treatment using ExAblate 2100 system (InSightec), under IRB approval. Post-surgery pathology evaluation test the efficacy of the treatment.

No significant complications were observed in all subjects during or immediately after the procedure. In 10 patients, multiparametric MRI no shows enhancement at breast treatment area. Post-surgery histological evaluation confirmed the absence of residual neoplastic foci in necrotic tissue area with at least 5 mm margins of normal breast tissue in all 10 patients. In 2 cases treatment failed due to transducer malfunction, and pathologist observed 15% of residual tumor. Results demonstrate excellent agreement between pathology and post-treatment MRI.

MRgFUS is a promise treatment to determines focal and noninvasive excision of unifocal breast cancer, according to histopathology findings.

MRgFUS is an innovative incisionless technique to obtained reliable ablation of invasive breast cancer and successful clinical outcome.

Read MR-guided Ultrasound Offers Noninvasive Treatment for Breast Cancer, RSNA Press Release, 4 Dec 2013

Sources: Clinical Experience in Noninvasive Treatment of Focal Breast Cancer with Magnetic Resonance Guided High Intensity
Focused Ultrasound (MRgFUS)
, RSNA, 4 Dec 2013

Related: Sound Waves as Breast Cancer Tx: Wave of Future?
by Kristina Fiore, 6 Dec 2013

Our posts about Breast Cancer – Screening – Women’s Health

What is Robotic Surgery? Advantages Disadvantages compared to Laparoscopy and Laparotomy

Is robotic surgery right for everyone?

What is robotic surgery?
ASRM is a non-profit organization devoted to advancing knowledge and expertise in reproductive medicine including infertility, menopause, and sexuality.

The Patient Education Website of the American Society for Reproductive Medicine adresses these questions:

  • What is robotic surgery?
  • What are the advantages of robotic surgery compared to traditional laparoscopy?
  • What are the advantages of robotic surgery compared to laparotomy (open incision)?
  • Are there any disadvantages of robotic surgery?
  • What are the most common surgical procedures performed by robotic surgery?
  • Is robotic surgery right for everyone?

Read ASRM Robotic Surgery, American Society for Reprocutive Medicine, Revised 2012 – PDF.

Related posts:

%d bloggers like this: